Difference between revisions of "Essential thrombocythemia"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.''' Is ...")
 
(updated content)
Line 3: Line 3:
 
Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen?  Have you noticed an error?  Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]].
 
Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen?  Have you noticed an error?  Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]].
  
−
{{TOC limit|limit=3}}
+
{{TOC limit|limit=2}}
  
−
=Anagrelide (Agrylin)=
+
==Anagrelide (Agrylin)==
−
 
 
−
==Regimen #1, Harrison et al. 2005==
 
  
 +
===Regimen #1, Harrison et al. 2005===
 
*[[Anagrelide (Agrylin)]] 0.5 mg PO twice daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.")
 
*[[Anagrelide (Agrylin)]] 0.5 mg PO twice daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.")
−
*[[Aspirin]] 75 mg (100 mg in Australia) PO daily  
+
*[[Aspirin]] 75 mg (100 mg in Australia) PO once daily  
−
 
 
−
==Regimen #2, Gisslinger et al. 2013 (ANAHYDRET)==
 
−
''Doses were not specified for either arm of this study. Patients on aspirin or clopidogrel were allowed on study if they had been taking the medication(s) for at least two weeks.''
 
  
−
*[[Anagrelide (Agrylin)]]
+
===Regimen #2, Gisslinger et al. 2013 (ANAHYDRET)===
 +
*[[Anagrelide (Agrylin)]] 0.5 mg PO twice daily ("increased until maintenance of the platelet count at normal (≤450 x 10<sup>9</sup>/L) or close to normal levels (>450 x 10<sup>9</sup>/L to 600 x 10<sup>9</sup>/L)")
 +
*Neither [[aspirin]] nor [[Clopidogrel (Plavix)]] were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion
  
−
==References==
+
===References===
 
# Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. [http://www.nejm.org/doi/full/10.1056/NEJMoa043800#t=article link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16000354 PubMed]
 
# Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. [http://www.nejm.org/doi/full/10.1056/NEJMoa043800#t=article link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16000354 PubMed]
−
# Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. [http://bloodjournal.hematologylibrary.org/content/121/10/1720.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/23315161 PubMed]
+
# Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. [http://bloodjournal.hematologylibrary.org/content/121/10/1720.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23315161 PubMed]
−
 
 
−
=Hydroxyurea (Hydrea)=
 
−
 
 
−
==Regimen #1, Harrison et al. 2005==
 
  
−
*[[Hydroxyurea (Hydrea)]] 0.5 to 1 g PO daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.")
+
==Hydroxyurea (Hydrea)==
−
*[[Aspirin]] 75 mg (100 mg in Australia) PO daily
 
  
−
==Regimen #2, Gisslinger et al. 2013 (ANAHYDRET)==
+
===Regimen #1, Harrison et al. 2005===
−
''Doses were not specified for either arm of this study. Patients on aspirin or clopidogrel were allowed on study if they had been taking the medication(s) for at least two weeks.''
+
*[[Hydroxyurea (Hydrea)]] 500-1000 mg PO once daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.")
 +
*[[Aspirin]] 75 mg (100 mg in Australia) PO once daily
  
−
*[[Hydroxyurea (Hydrea)]]
+
===Regimen #2, Gisslinger et al. 2013 (ANAHYDRET)===
 +
*[[Hydroxyurea (Hydrea)]] 1500 mg PO once daily ("increased until maintenance of the platelet count at normal (≤450 x 10<sup>9</sup>/L) or close to normal levels (>450 x 10<sup>9</sup>/L to 600 x 10<sup>9</sup>/L)")
 +
*Neither [[aspirin]] nor [[Clopidogrel (Plavix)]] were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion
  
−
==References==
+
===References===
 
# Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. [http://www.nejm.org/doi/full/10.1056/NEJMoa043800#t=article link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16000354 PubMed]
 
# Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. [http://www.nejm.org/doi/full/10.1056/NEJMoa043800#t=article link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16000354 PubMed]
−
# Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. [http://bloodjournal.hematologylibrary.org/content/121/10/1720.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/23315161 PubMed]
+
# Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. [http://bloodjournal.hematologylibrary.org/content/121/10/1720.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23315161 PubMed]

Revision as of 05:25, 2 April 2013

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.


Anagrelide (Agrylin)

Regimen #1, Harrison et al. 2005

  • Anagrelide (Agrylin) 0.5 mg PO twice daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.")
  • Aspirin 75 mg (100 mg in Australia) PO once daily

Regimen #2, Gisslinger et al. 2013 (ANAHYDRET)

  • Anagrelide (Agrylin) 0.5 mg PO twice daily ("increased until maintenance of the platelet count at normal (≤450 x 109/L) or close to normal levels (>450 x 109/L to 600 x 109/L)")
  • Neither aspirin nor Clopidogrel (Plavix) were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion

References

  1. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. link to original article contains verified protocol PubMed
  2. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. link to original article contains verified protocol PubMed

Hydroxyurea (Hydrea)

Regimen #1, Harrison et al. 2005

  • Hydroxyurea (Hydrea) 500-1000 mg PO once daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.")
  • Aspirin 75 mg (100 mg in Australia) PO once daily

Regimen #2, Gisslinger et al. 2013 (ANAHYDRET)

  • Hydroxyurea (Hydrea) 1500 mg PO once daily ("increased until maintenance of the platelet count at normal (≤450 x 109/L) or close to normal levels (>450 x 109/L to 600 x 109/L)")
  • Neither aspirin nor Clopidogrel (Plavix) were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion

References

  1. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. link to original article contains verified protocol PubMed
  2. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. link to original article contains verified protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Essential_thrombocythemia&oldid=2672"